{
    "nctId": "NCT00977119",
    "briefTitle": "Investigation of Genetic Determinants of Capecitabine Toxicity",
    "officialTitle": "Investigation of Genetic Determinants of Capecitabine Toxicity",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 240,
    "primaryOutcomeMeasure": "Genetic variants of toxicity",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* women with breast cancer in whom single agent capecitabine therapy is being considered\n* aged 18 years and older\n\nExclusion Criteria:\n\n* patients who have previously received capecitabine are excluded\n* patients cannot be receiving capecitabine in combination with another cancer chemotherapy; concurrent use of trastuzumab is not permitted; concurrent use of zoledronic acid is allowed\n* serum albumin less than 3.0 g/dL within the last 30 days\n* creatinine clearance (CrCL) or glomerular filtration rate (GFR) less than 60 mL/min \\[/body surface area (BSA)\\] (within the last 30 days)\n* inability to understand and give informed consent to participate\n* patients with a history of inflammatory bowel disease requiring therapy or patients with chronic diarrhea syndromes or paralytic ileus\n* patients with prior or concurrent pelvic irradiation\n* patients who use an ostomy for fecal excretion\n* there is no limit on the number of prior chemotherapies; the decision to use capecitabine is determined solely by the treating physician",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}